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2009; Visser et al., 2009). However, differentiating AD from other 
neurodegenerative diseases remains a problem. Furthermore, it is 
evident that the disease mechanism of AD is very complex, involv-
ing inflammation, oxidative stress, endocrine dyscrasia, apoptosis, 
and other brain pathologies. It is possible that these processes can 
be monitored by CSF biomarkers, which could be useful in clinical 
practice and in research (Mattsson et al., 2009a).
The general aim of this study was to test the performance of 
two biochip arrays that measure biomarkers reflecting different 
aspects of brain injury. To that end, we analyzed 80 plasma and 
CSF samples from a well-documented clinical material, consist-
ing of patients with AD, vascular dementia (VAD), frontotemporal 
dementia (FTD), dementia with Lewy bodies (DLB), or MCI, as 
well as cognitively healthy controls.
MATERIALS AND METHODS
STuDy pARTIcIpANTS
The study included 60 patients admitted to a memory clinic in 
Falköping, Sweden, for evaluation of cognitive impairment. A con-
trol group of 20 healthy age-matched individuals from the same 
geographical area was also included. Controls were recruited among 
INTRODucTION
Neurodegenerative diseases are important worldwide health issues 
and include several diseases that share similar features (Jellinger, 
2010), which can pose a diagnostic challenge. An objective way of 
measuring  disease-specific  processes  is  provided  by  biomarkers 
(Blennow et al., 2010). Biomarkers have several potential uses, as 
illustrated in the context of Alzheimer’s disease (AD). They can be 
applied in diagnosis and in monitoring disease progression (Hampel 
et al., 2010). They may also be used in clinical trials and in drug 
development, to identify and monitor biochemical drug effects, or to 
detect possible side effects (Hampel et al., 2010). The best-established 
biomarkers for AD are cerebrospinal fluid (CSF) levels of total tau 
(T-tau), which reflects cortical axonal degeneration; hyperphospho-
rylated tau (P-tau), which reflects neurofibrillary tangle pathology; 
and the 42 amino acid isoform of amyloid β (Aβ1-42), which reflects 
amyloid pathology (Blennow et al., 2010). Numerous studies have 
shown that a pathological signature of elevated CSF T-tau and P-tau 
with reduced Aβ1-42 identifies AD with dementia, as well as incipient 
AD in patients with mild cognitive impairment (MCI), with sensitiv-
ity and specificity figures of 75–95% (Zetterberg et al., 2003; Herukka 
et al., 2005; Hansson et al., 2006; Mattsson et al., 2009b; Shaw et al., 
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doi: 10.3389/fnagi.2011.00001(Randox Laboratories, Antrim, UK). CRB I tests for brain-derived 
neurotrophic factor (BDNF), heart-type fatty acid-binding protein 
(FABP), glial fibrillary acidic protein (GFAP), and interleukin-6 
(IL6). CRB II tests for neuron-specific enolase (NSE), neutrophil 
gelatinase-associated lipocalin (NGAL), soluble tumor necrosis 
factor receptor I (TNFRI), D-dimer (DDMER), thrombomodulin 
(TM), and C-reactive protein (CRP). The analyses were performed 
according to the instructions from the manufacturer with some 
minor modifications, which are outlined below. A summary of the 
candidate biomarkers and their potential relation to brain injury 
is given in Table 2.
In the analysis of plasma with CRB I, 100 μL of sample, calibrator, 
or control was added to each site of the biochip with 200 μL of assay 
buffer. The chip was then incubated for 45 min at 37°C. Unbound 
reagents were removed manually by two quick washes and four 
soaking periods. Following the addition of 300 μL of conjugate to 
each well, a second incubation of 45 min at 37°C was carried out. 
After six wash cycles, 250 μL of signal reagent (luminol and peroxide 
in a 1:1 ratio) was added. When 2 min had passed, the biochip was 
imaged in the Randox Evidence™ Investigator System.
The assay procedure for the analysis of plasma with CRB II dif-
fered from that of CRB I in some points. All calibrators, controls 
and samples were prediluted with dilution buffer in a clean vessel 
in a 1:8 ratio (35 μL plus 245 μL). For the samples originating from 
plasma, 200 μL of the prediluted sample and 100 μL of assay buffer 
were added to each well. The remaining procedure was identical 
to CRB I.
To increase the sensitivity of the assay, larger volumes of CSF 
than volumes of plasma were used. When analyzing CSF with CRB 
I, a sample volume of 200 μL was used, and the values obtained 
were therefore divided by 2. In the analysis of CSF with CRB II, 
the sample was prediluted in a 1:2 ratio instead of a 1:8 ratio. The 
values obtained were therefore divided by 4.
spouses of the patients and by advertisement in local newspapers. 
The participants were recruited during the years 2000–2008. The 
controls underwent a normal neurological and psychiatric examina-
tion and had no subjective symptoms of cognitive dysfunction.
The DSM-IIIR criteria for dementia and the criteria for prob-
able AD defined by NINCDS-ADRDA (McKhann et al., 1984) were 
used for AD diagnosis. Some AD patients showed signs of vascular 
pathology in brain imaging and were assigned to a separate group 
called “AD with cerebrovascular pathology” (MIX). The diagnosis 
MCI was made according to the criteria established by Petersen et al. 
(1999). Some MCI patients did not deteriorate during follow-up 
(median duration 3 years, range 1–7 years), and these are called 
“stable MCI patients” (SMCI) in this study. Subjects fulfilling the 
DSM-IIIR criteria for dementia (American Psychiatric Association, 
1987) and the requirements for VAD defined by NINDS-AIREN 
(Roman et al., 1993) or VAD of the subcortical type according to 
the guidelines by Erkinjuntti et al. (2000) were given the diagnosis 
“VAD”. Patients who were diagnosed with DLB met the consen-
sus criteria defined by McKeith et al. (1999). FTD was diagnosed 
through the criteria defined by Neary et al. (1998). Demographics 
and clinical characteristics are presented in Table 1. The partici-
pants have been previously described (Mattsson et al., 2010).
pLASMA AND cSF SAMpLINg
Plasma samples were collected in the morning in EDTA tubes by 
venipuncture. The samples were centrifuged, aliquoted, and stored 
at −70°C pending biochemical analyses, without being thawed and 
re-frozen. CSF samples were collected by lumbar puncture in the L3/
L4 or L4/L5 interspace at the standardized time point 8.30–9.00 am. 
The first 12 mL of CSF was collected in a polypropylene tube and 
centrifuged at 2,000×g at +4°C for 10 min. The supernatant was 
pipetted off, gently mixed to avoid possible gradient effects, and 
aliquoted in polypropylene tubes that were stored at −70°C pending 
biochemical analyses, without being thawed and re-frozen.
BIOcHEMIcAL ANALySES
Biochemical analyses were performed using the Randox biochip 
array  technology  (Fitzgerald  et  al.,  2005).  Measurements  were 
made using the Randox Cerebral Arrays I (CRB I) and II (CRB II) 
Table 1 | Demographics of the study population.
  ALL  CONTROL  SMCI  AD  VAD  MIX  OTHER
N  80  20  13  24  10  8  5
Age  65–81  65–81  65–77  66–80  67–79  71–80  67–76
Sex M/F  40/40  10/10  5/8  11/13  7/3  4/4  3/2
MMSE  26  28  29  23  24  21  19
ALL,  all  study  participants;  CONTROL,  cognitively  healthy  control  subjects; 
SMCI, stable mild cognitive impairment; AD, Alzheimer’s disease. The AD group 
consisted of patients with AD and patients with MCI who converted to AD during 
the course of the study. VAD, vascular dementia. The VAD group consisted of 
patients with VAD and patients with MCI who converted to VAD during the course 
of the study. The MIX group consisted of patients with both AD and VAD and MCI 
who converted to AD and VAD during the course of the study. The group named 
OTHER consisted of patients with dementia with Lewy bodies and MCI who 
converted to frontotemporal dementia during the course of the study. MMSE, 
mini mental state examination. Displayed MMSE values are group medians.
Table 2 | Summary of tested candidate biomarkers.
Biomarker Potential association to brain injury
Brain-derived neurotrophic 
factor (BDNF)
A neurotrophin upregulated in 
response to neuronal injury
Heart-type fatty acid-binding 
protein (FABP)
Highly expressed in neurons
Glial fibrillary acidic protein 
(GFAP)
Highly expressed in astrocytes
Interleukin-6 (IL6) Increased expression in response 
to stroke
Neuron-specific enolase (NSE) Highly expressed in neurons
Neutrophil gelatinase-
associated lipocalin (NGAL)
Unclear
Soluble tumor necrosis factor 
receptor I (TNFRI)
A cell receptor that can be shedded in 
response to neuronal injury
D-dimer (DDMER) Involved in coagulation and may 
reflect cerebrovascular disease
Thrombomodulin (TM) Involved in coagulation and may 
reflect cerebrovascular disease
C-reactive protein (CRP) May reflect low-grade inflammation in 
cerebrovascular disease
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(Figures 5 and 6), although there was some overlap. The robust-
ness of the models was estimated using the quality parameters 
R2Y and Q2. Although no clear-cut levels exist for when a model 
should be rejected, the relatively low Q2: R2Y ratios for the AD vs 
MIX, VAD vs MIX, and control vs MIX comparisons indicate that 
these models should be interpreted with caution (Table 3). The 
variable importance in projection (VIP) plots show clearly that 
the contributions of the individual analytes to the separation of 
the diagnostic groups differed. The most important analyte for 
separating AD from all other groups was FABP. In the separation 
of VAD and control, GFAP in CSF had the most impact, although 
many other analytes contributed.
cORRELATIONS BETwEEN pLASMA AND cSF LEvELS OF THE DIFFERENT 
MARkERS
We examined the correlations between plasma and CSF levels of the 
markers. There were no significant correlations for most markers. 
The only exceptions were DDMER, where plasma levels decreased 
with high CSF levels (r = −0.37, p = 0.044) and NGAL, where there 
was a positive correlation between plasma and CSF levels (R = 0.45, 
p < 0.0001).
DIScuSSION
Cerebrospinal fluid biomarkers have several usages in AD and will 
play a yet more important role if disease-modifying drugs become 
available (Blennow et al., 2010). Due to the complex nature of AD, 
and the overlap in pathology between neurodegenerative diseases, 
a multimarker strategy may be a key factor in clinical practice and 
in research. Several interesting potential biomarkers for AD have 
been described (Hu et al., 2010), but the results have been dif-
ficult to replicate, especially for markers in blood (Blennow et al., 
2010). Although it is tempting to use blood-based biomarkers due 
to the easy accessibility of samples, CSF biomarkers have so far 
proved to be superior. This is probably due to the closer proximity 
of CSF to the brain tissue, and thereby to pathological processes 
in the brain.
We have been able to measure a number of analytes poten-
tially related to neurodegeneration in both CSF and plasma from a 
clinically well-defined material of patients with neurodegenerative 
disorders using the Randox biochip method. The findings included 
elevated levels of CSF FABP in patients with AD and elevated lev-
els of CSF GFAP, CSF NGAL, and plasma DDMER in patients 
with cerebrovascular disease. Notably, there was a large overlap in 
biomarker levels across the diagnostic groups and no biomarker 
was by itself disease-specific.
Fatty acid-binding protein is a small protein involved in the 
uptake,  transport,  and  metabolism  of  fatty  acids  (Storch  and 
McDermott, 2009). Nine different isoforms of FABP have been 
identified, and each has a specific pattern of tissue distribution. 
Heart-type FABP is expressed in the brain and in other organs, and 
has been identified as a potential marker for brain injury (Pelsers 
et al., 2005). In our study, CSF levels of FABP were clearly elevated 
in patients with AD, those with incipient AD, and those with clinical 
AD and concomitant cerebrovascular disease. These data are con-
sistent with previous findings (Steinacker et al., 2004), and suggest 
that FABP has a potential role as a biomarker for AD.
We used the limits of detection (LODs) provided in the Randox 
array manuals for CRB I and CRB II. The applicability of these 
detections limits was assessed by examining the standard curves. 
The standard curve-derived LODs agreed with the values in the 
manuals in all cases except for CRP for which a more accurate LOD 
was assigned. The employed LODs were as follows: BDNF = 0.59 pg/
mL, FABP = 0.29 ng/mL, GFAP = 0.18 ng/mL, IL6 = 0.64 pg/mL, 
NSE = 0.26 ng/mL, NGAL = 17.8 ng/mL, TNFRI = 0.24 ng/mL, 
D-dimer = 2.1 ng/mL, TM = 0.5 ng/mL, CRP = 1.8 mg/L.
STATISTIcAL ANALySIS
The correlations of the analyte levels with the diagnostic groups 
were determined using GraphPad Prism 5 (GraphPad Software 
Inc., La Jolla, USA). As the distribution of quantitative measures 
was significantly skewed, statistical tests involving these variables 
were  conducted  using  the  non-parametric  Kruskal–Wallis  test 
for multiple variables using Dunn’s post hoc test, followed by the 
Mann–Whitney U-test for pair-wise comparisons. A p-value lower 
than 0.05 was used as a limit for significant difference between the 
diagnostic groups. Differences in the pattern of biomarkers between 
the diagnostic groups were investigated through multivariate dis-
criminant analysis (DA) using the orthogonal projection to latent 
structures (OPLS) algorithm (Bylesjö et al., 2007) implemented in 
the software SIMCA P+ (v. 12, Umetrics, Umeå, Sweden). The qual-
ity of the models was assessed by the relationship between the total 
amount of explained (R2Y) and predicted (Q2) class-variation.
RESuLTS
pERFORMANcE OF THE ARRAyS
Detectable levels of most analytes were found in both CSF and 
plasma (Figures 1–4). Detectable levels were found in less than half 
of subjects for CSF BDNF and DDMER, and plasma CRP, GFAP, 
and TNFRI. It was not possible to detect CRP in CSF in any patient. 
One sample of CSF was missing, making it impossible to measure 
BDNF, IL6, FABP, and GFAP in one patient with AD.
LEvELS OF BIOMARkERS IN THE DIAgNOSTIc gROupS
The univariate statistics showed that four biomarkers differed sig-
nificantly between some of the diagnostic groups. FABP in CSF 
was higher in AD subjects than it was in controls (p < 0.01) and in 
patients with VAD (p < 0.001; Figure 1C). Subjects with VAD had 
higher levels of GFAP in CSF than controls (p < 0.001; Figure 2A). 
Measurements  of  DDMER  in  plasma  showed  higher  levels  in 
patients with VAD than in those with SMCI (p < 0.01) and higher 
levels in those with SMCI than in controls (p < 0.01; Figure 2E). 
NGAL in CSF was higher in AD patients with vascular risk factors 
(MIX) than it was in those with SMCI (p < 0.001) and in those with 
AD (p < 0.01; Figure 3A). Only the p-values below 0.001 survived 
Bonferroni correction for multiple comparisons.
MuLTIMARkER cOMpARISONS BETwEEN DIAgNOSTIc gROupS
The controls and SMCI were merged into one group in the multi-
variate analysis. This was justified by the lack of significant differ-
ences between the two groups for most markers in the univariate 
analysis and the knowledge that patients with stable MCI most 
often do not suffer from a progressive neurodegenerative disor-
der (Hampel et al., 2010). The models demonstrated differences 
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2000). Increased levels of GFAP have been found in the CSF and 
blood of patients with various neurological conditions (Lamers 
Cerebrospinal fluid levels of GFAP were higher in patients with 
VAD than in controls. GFAP is a monomeric intermediate fila-
ment protein expressed almost exclusively in astrocytes, where it 
FIguRE 1 | Levels of analytes in plasma and CSF. (A–C) Show values obtained in CSF , and (D–F) display values obtained in plasma. Significant differences 
between diagnostic groups are shown by brackets. Straight lines indicate median values.
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for neutrophil activation (Xu and Venge, 2000). The importance of 
elevated NGAL in the context of neurodegenerative diseases is not 
known, and this must be verified and further evaluated. The ten-
dency toward different NGAL levels in the control and SMCI groups 
is peculiar and calls for caution when interpreting the data.
et al., 2003), including patients with AD and VAD (Verbeek et al., 
2003). We conclude that increased levels of GFAP are not specific 
for any neurodegenerative disease.
Patients with AD and vascular risk factors had higher levels of 
NGAL in CSF than patients with SMCI and pure AD. NGAL is a 
protein found in the granules of neutrophils. It is released when the 
FIguRE 2 | Levels of analytes in plasma and CSF. (A–C) Show values obtained in CSF , and (D–F) display values obtained in plasma. Significant differences 
between diagnostic groups are shown by brackets. Straight lines indicate median values.
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Rosén et al.  Biochip-derived protein patterns in neurodegenerative diseasesFIguRE 3 | Levels of analytes in plasma and CSF. (A–C) Show values obtained in CSF , and (D–F) display values obtained in plasma. Significant differences 
between diagnostic groups are shown by brackets. Straight lines indicate median values.
D-dimer is a product of the plasmin-mediated breakdown of 
fibrin (Keeling et al., 2004) and increased plasma levels have previ-
ously been associated with VAD (Gupta et al., 2005). This is con-
firmed by our findings.
The multivariate statistical model succeeded in separating the 
diagnostic groups, although with some overlap. Only some of the 
biomarkers contributed significantly to the separations, which is 
indicated by the VIP plots. This may be considered in the future 
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FIguRE 5 | Scatter plots and VIP tables for the groups compared. (A–C) Show scatter plots from OPLS-DA, while (D–F) display the corresponding variable 
importance in projection (VIP) plots. A black bar indicates an elevated level of the analyte in the disease group, whereas a white bar indicates an elevated level in the 
control group. The analytes that contribute significantly to the separation of the diagnostic groups are marked with a bracket.
design of biochips, providing chips that are equipped only with 
antibodies relevant for certain applications. Bearing in mind the 
low Q2 to R2Y ratios, there is a large uncertainty concerning the 
multivariate comparisons for AD vs MIX, VAD vs MIX, and con-
trol vs MIX. One probable explanation for the poor ratio is the 
small size of the MIX diagnostic group. The results from the mul-
tivariate statistics as such may only be valid for the population 
studied. Thus, more studies are required to verify the model in 
other populations.
In summary, we have shown that the biochip arrays studied 
can be applied to samples of plasma and CSF. Some statistically 
significant differences in biomarker concentrations were seen in 
the different diagnostic groups but none of the tested markers was 
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Rosén et al.  Biochip-derived protein patterns in neurodegenerative diseasesFIguRE 6 | Scatter plots and VIP tables for the groups compared. 
(A–C) Show scatter plots from OPLS-DA, while (D–F) display the corresponding 
variable importance in projection (VIP) plots. In the upper two VIP tables, the 
white bars represent an elevated level of the analyte in AD, and a black bar 
represents an elevated level in the other group. In the lower VIP plot, elevated 
levels in VAD are represented by white bars and in MIX by black bars. The 
analytes that contribute significantly to the separation of the diagnostic groups 
are marked with a bracket.
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